XOMA Corporation (XOMA)

Check out top investors' recommendation for XOMA
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet’s uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company’s proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 15, '19     36.00  Jan 15, '20  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 21, '18     49.00  Sep 21, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   May 21, '18     33.00  May 21, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 09, '18     49.00  Mar 09, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Feb 06, '18     33.00  Feb 06, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 18, '18     49.00  Jan 18, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Dec 19, '17     33.00  Dec 19, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Dec 07, '17     38.00  Dec 07, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 17, '17     38.00  Oct 17, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Sep 05, '17     19.00  Sep 05, '18  N/A 
Carol Werther Summer Street Research Buy   Aug 10, '17     15.00  Aug 10, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Mar 11, '16   18.00  3.00  Mar 11, '17  -66.39% 
Liana Moussatos Wedbush Securities Inc. Buy   Nov 19, '15   28.40  6.00  Nov 19, '16  -76.58% 
Liana Moussatos Wedbush Securities Inc. Buy   Oct 02, '15   0.99  6.00  Oct 02, '16  -53.54% 
Liana Moussatos Wedbush Securities Inc. Buy   May 28, '15   3.58    May 28, '16  -80.45% 
Matthew Kaplan Ladenburg Thalmann & Co. Buy   Mar 12, '15   3.78    Mar 12, '16  -76.19% 
Liana Moussatos Wedbush Securities Inc. Buy   Mar 09, '15   3.75    Mar 09, '16  -76.53% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Nov 14, '14   3.92    Nov 14, '15  -65.31% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Oct 10, '14   3.70    Oct 10, '15  -73.24% 
Matthew Kaplan Ladenburg Thalmann & Co. Buy   May 09, '14   3.64    May 09, '15  1.65% 
< previous12